Join the Loyalty Program for Discounts

How Breast Cancer Affects Bone Health

Article at-a-glance:

  • Up to 80% of patients with breast cancer lose bone.
  • Breast cancer patients hospitalized for a fracture have an 83% increased risk of dying.
  • Learn the causes of bone loss and increased fractures, and what you can do do decrease your risks.
Anxiety Word Cloud

By Dr. John Neustadt

The American Cancer Society estimates that one in eight women will be diagnosed with breast cancer in their lifetime, and this year alone, there will be nearly 300,000 new cases.1 Many of those cancers will be estrogen receptor-positive (ER+). Because in these cancers, estrogen can worsen the condition, the standard of care is to prescribe a medication that suppresses estrogen production. This class of drugs is called aromatase inhibitors (AI). Some drugs in the category include anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara).

The Risk

The bone-damaging effect of these medications is well documented. It’s so common that up to 80% of patients with breast cancer lose bone because of these drugs.2,3 The consequences are deadly. Patients with breast cancer who are hospitalized for a fracture have an 83% higher risk of dying compared to breast cancer patients who don’t fracture.4 

The medications are powerful bone destroyers. AIs increase bone loss up to four times faster than naturally losing bone when a woman goes through menopause. It’s been estimated that 20% of women taking one of these drugs for five years will break a bone. This means that 1 in every five women on long-term AI therapy will experience an AI-related fracture.5

How AIs Damage Bone

How AIs damage bone has been studied for years. Estrogen helps maintain strong bones, so when estrogen decreases, bone loss follows. AIs reduce estrogen levels even more than what happens during menopause, and that sets off a cascade of events that destroys bone and increases fracture risk.6-9 

Low estrogen activates the immune system to increase inflammation and bone-damaging chemicals. Interleukin 7 (IL-7) is a chemical signal your immune system produces. Low estrogen increases IL-7, activating a complex cascade that increases damaging free radicals and reactive oxygen species (ROS). In turn, this activates receptor activator of nuclear factor kappa-Β ligand (RANKL) and tumor necrosis factor alpha (TNFα).10 The net result is that estrogen deficiency increases osteoclasts, the cells in your bones that destroy bone, and how long osteoclasts live. This causes more and faster bone loss.11

Testing for Bone Loss

If you’re taking an AI, getting your bones tested is important. Most expert panels recommend a bone density test before starting an AI and every one to two years. Unfortunately, however, most patients are not getting this testing done. Only 34.5% of cancer patients taking AIs are screened with baseline and follow-up bone density scans.12 Therefore, speak with your doctor and ensure you get the recommended testing. 

Natural Approaches

If you need to stay on the AI medication, there are many things you can do to reduce your fracture risk, which I discuss in my book, Fracture-Proof Your Bones. These include improving bone health through diet and exercise, such as the Stork exercise, which can increase balance and reduce your risk for falls and fractures. 

Identifying Other Dangerous Drugs

One important thing to look at is whether you’re taking other medications that destroy bone and increase your risk. According to the data, it’s likely that you are. Medications are so common that 44% of men and 57% of women 65 years old or older are taking at least five medications, while 12% of people in this age group take ten or more medications.13 

Even lots of younger folks are taking meds. In the United States and Canada, where overall prescribing rates are similar, nearly 70% of adults 40-79 years old take at least one prescription drug, which increases to about 83% for people 60 years old or older.14 

As I discuss in my book, many medications damage bones and the bottom line is that people are taking a lot of drugs. Taking them along with an AI can magnify the damage. You can talk to your doctor about this, but your local pharmacist is also an important person to speak with. Switching to a safer medication, decreasing the dose, or discontinuing it altogether may be possible. 

Prolia, a Good Option for You? 

Conventionally, the bone medication denosumab (Prolia) has been studied in women taking aromatase inhibitors with favorable results. The clinical trial enrolled 3,425 postmenopausal women with hormone receptor-positive (HR+) breast cancer who were taking an AI medication. The patients were given a Prolia injection every six months and followed the women for eight years. Not only did the women taking Prolia have a 20% decrease in bone metastasis, but they also had a 26% increase in overall survival.15 A second clinical trial with breast cancer patients taking Prolia for three years showed a 49% decrease in fractures.16

If You Liked This, You Might Also Enjoy

How Omega-3s Affect Your Brain

How to Ensure You Get the Best Supplements

Top 10 Non-Dairy Sources of Calcium


1 Key Statistics for Breast Cancer. American Cancer Society. Accessed September 20, 2023.

2 Chen Z, Maricic M, Pettinger M, et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer. Oct 1 2005;104(7):1520-30. doi:10.1002/cncr.21335

3 Lindsey AM, Gross G, Twiss J, Waltman N, Ott C, Moore TE. Postmenopausal survivors of breast cancer at risk for osteoporosis: nutritional intake and body size. Cancer Nurs. Feb 2002;25(1):50-6. doi:10.1097/00002820-200202000-00010

4 Colzani E, Clements M, Johansson AL, et al. Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br J Cancer. Nov 22 2016;115(11):1400-1407. doi:10.1038/bjc.2016.314

5 Hadji P, Aapro MS, Body JJ, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. Jun 2017;7:1-12. doi:10.1016/j.jbo.2017.03.001

6 Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Critical reviews in oncology/hematology. 2009/01/01/ 2009;69(1):73-82. doi:

7 Hadji P. Cancer Treatment-Induced Bone Loss in women with breast cancer. Bonekey Rep. 2015;4:692. doi:10.1038/bonekey.2015.60

8 Hadji P, Asmar L, van Nes JG, et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol. Jun 2011;137(6):1015-25. doi:10.1007/s00432-010-0964-y

9 Lee SJ, Kim KM, Brown JK, et al. Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer. Calcified Tissue International. 2015/12/01 2015;97(6):551-559. doi:10.1007/s00223-015-0046-x

10 Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci. Nov 2007;1116:360-75. doi:10.1196/annals.1402.068

11Faienza MF, Ventura A, Marzano F, Cavallo L. Postmenopausal Osteoporosis: The Role of Immune System Cells. Clinical and Developmental Immunology. 2013/05/23 2013;2013:575936. doi:10.1155/2013/575936

12Stratton J, Hu X, Soulos PR, Davidoff AJ, Pusztai L, Gross CP, Mougalian SS. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors. Journal of Oncology Practice. 2017;13(5):e505-e515. doi:10.1200/jop.2016.018341

13Woodruff K. Preventing polypharmacy in older adults. American Nurse Association. Accessed January 18, 2021.

14Hales CM, Servais J, Martin CB, Kohen D. Prescription Drug Use Among Adults Aged 40-79 in the United States and Canada. NCHS Data Brief. Aug 2019;(347):1-8.

15Gnant M, Frantal S, Pfeiler G, et al. Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial. Journal of Clinical Oncology. 2022;40(16_suppl):507-507. doi:10.1200/JCO.2022.40.16_suppl.507

16Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. Aug 1 2015;386(9992):433-43. doi:10.1016/s0140-6736(15)60995-3


Your Body was Built to Move

Your Body was Built to Move

  Article at-a-glance: Despite the fact that our bodies were built to move, the average adult spends more than half of their waking hours being sedentary. Not moving your body enough increases risk for depression, heart disease, cancer, osteoporosis, and dying...

Top Heart Attack Symptoms in Women

Top Heart Attack Symptoms in Women

Someone in the US dies from heart disease about every 37 seconds, making it the number one killer of adults. Unfortunately, women are often at a disadvantage compared to men when it comes to getting the proper evaluation and treatment. One challenge is that the unique symptoms experienced by women aren’t recognized as heart-related. Women also tend to wait longer than men to get medical attention.

But that’s only part of the story. Even when women report their symptoms to their healthcare provider, more than half the time their concerns are dismissed as not related to their heart. As a result, women are less likely than men to get a proper workup. Knowing the symptoms, insisting your concerns are taken seriously, and getting a cardiac evaluation can save your life.

MK4 or MK7, Which is Better for Bones?

MK4 or MK7, Which is Better for Bones?

MK4 and MK7 are two forms of vitamin K2 commonly found in dietary supplements. Both are naturally occurring, and both have health benefits. But which one is better? When should you take one instead of the other? This article answers these questions so you can make the best possible decision for your health.

Share This